Novartis AG - ADR
NVS
Market Cap$227.71B
Close$
Earnings Call Q1 2025
April 29, 2025 - AI Summary
Strong Q1 Performance: Novartis reported a 15% increase in net sales and a 27% rise in core operating income for Q1 2025. The core margin improved by 400 basis points to reach 42.1%. These results support an upgrade in full-year guidance to high single-digit sales growth and low double-digit core operating income growth.
Innovative Pipeline Progress: The company highlighted significant strides in its pipeline, with three new drug approvals in quick succession (Pluvicto, Vanrafia, and Fabhalta). Pluvicto is particularly notable, with expectations for peak sales guidance restored to $5 billion. The FDA approval of the PSMAfore indication is expected to bolster growth in the second half of the year.
Pipeline and Market Expansion Plans: Novartis emphasized continued investment in innovative therapies, including expanding their radioligand therapy capabilities and preparations for the launch of OAV-101 gene therapy. There are also ambitions for entering new therapeutic areas such as Sjogren's with ianalumab, which could represent multibillion-dollar market potential.
Exclusive for Stockcircle Pro members
Sign up
$138.85
12.1% upside
Current Fair Value
12.1% upsideUndervalued by 12.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $227.71 Billion |
|---|---|
| Enterprise Value | $251.68 Billion |
| Dividend Yield | $3.994 (2.90697559491663%) |
| Earnings per Share | $5.92 |
| Beta | 0.53 |
| Outstanding Shares | 1,968,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 18.43 |
|---|---|
| PEG | 50.86 |
| Price to Sales | 4.76 |
| Price to Book Ratio | 2.48 |
| Enterprise Value to Revenue | 4.76 |
| Enterprise Value to EBIT | 15.8 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.81 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Novartis AG
CEO: Vasant Narasimhan Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...